Pentraxin 3 (PTX3) emerges as a promising future biomarker for detecting vascular inflammation in coronary artery disease (CAD), offering greater specificity than hsCRP or IL-6 by localizing primarily to atherosclerotic lesions rather than reflecting systemic inflammation. Here, IL6 is linked to coronary artery disorder.